Study Background
Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by absolute insulin deficiency, necessitating lifelong insulin therapy and vigilant glucose monitoring. Despite widespread adoption of continuous glucose monitoring (CGM) and intermittent scanning continuous glucose monitoring (isCGM) technologies, many adults with T1D fail to achieve recommended glycemic targets. Persistent hyperglycemia increases risk for microvascular and macrovascular complications, highlighting a significant unmet clinical need for interventions that enhance glycemic management beyond technology alone.
